Braveheart Bio, Inc. (BRVE)

NASDAQ: BRVE · Real-Time Price · USD

26.95

+0.67 (2.55%)

Sep 2, 2026, 4:00 PM EDT - Market closed

Braveheart Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
Selling, General & Admin	7.15	3.02
Research & Development	12.31	1.49
Operating Expenses	19.46	4.51
Operating Income	-19.46	-4.51
Interest & Investment Income	1.47	0.7
Other Non Operating Income (Expenses)	-0	0
EBT Excluding Unusual Items	-17.99	-3.81
Pretax Income	-80.23	-66.05
Net Income	-80.23	-66.05
Net Income to Common	-80.23	-66.05
Net Income Growth	-	-
Shares Outstanding (Basic)	30	17
Shares Outstanding (Diluted)	30	17
Shares Change	-	-
EPS (Basic)	-2.63	-3.93
EPS (Diluted)	-2.63	-3.93
EPS Growth	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025
EBIT	-19.46	-4.51

SEC Filings: 10-K · 10-Q